Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 15/20 | 0.61 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396730 | 0.86 | MC4R (0.61) | MC4RCNR2OPRM1BCHE | |
| Hydrochloric Acid SCHEMBL4399407 | 0.86 | MC4R (0.61) | MC4RCNR2OPRM1BCHE | |
| SCHEMBL5256358 | 0.85 | MC4R (0.44) | MC4RCNR2OPRM1 | |
| SCHEMBL4521447 | 0.82 | KIF11 (0.46) | MC4RCNR2OPRM1 | |
| SCHEMBL4398780 | 0.81 | MC4R (0.61) | MC4RCNR2OPRM1BCHE | |
| SCHEMBL4394233 | 0.81 | MC4R (0.79) | MC4RCNR2OPRM1BCHE | |
| Hydrochloric Acid SCHEMBL4403536 | 0.80 | MC4R (0.78) | MC4RCNR2OPRM1BCHE | |
| SCHEMBL5242526 | 0.78 | MC4R (0.81) | MC4R | |
| SCHEMBL4394018 | 0.77 | MC4R (0.64) | MC4RCNR2OPRM1BCHE | |
| SCHEMBL3794037 | 0.77 | MC4R (1.00) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| EP-1467974-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOD CONSEILS RECH APPLIC (FR) | 2007-08-15 | — | — | EP | disclosed |
| US-20050049290-A1 | Benzimidazole derivatives and their use as gnrh antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2005-03-03 | — | — | US | disclosed |
| EP-1467974-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (FR) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003053939-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049290-A1 | Benzimidazole derivatives and their use as gnrh antagonists | GNRHR, FSHR, KISS1R | MC4R 41/4885CNR2 758/4885OPRM1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.